服务热线:4008-750-250 | 客户留言

【细胞】周边试剂

细胞培养好坏,周边试剂(血清、培养基、添加因子)是关键,尤其出现在两个实验室之间过渡的情况,更是推荐从我们这边采购培养基。

【细胞】GPCR靶点

 现代新药研发的关键首先是寻找,确定和制备药物作用靶点。在500多个已发现的药物靶点里中,GPCR,Ion Channel,Kinase使用的最为广泛。 GPCR (G蛋白偶联受体),是细胞信号传导中的重要蛋白质,其拓扑构象为7次跨膜的受体。当膜外的配体作用于该受体时,该受体的膜内部分与G蛋白相互结合激活G蛋白,进而启动不同的信号转导通路并引起各种生物效应。构建一个GPCR过表达的稳定细胞系能够广泛用于筛选药物,研究各类疾病病因和发病机理。

【细胞】激酶靶点

 现代新药研发的关键首先是寻找,确定和制备药物作用靶点。在500多个已发现的药物靶点里中,GPCR,Ion Channel,Kinase使用的最为广泛。 激酶(kinase)是一类从高能供体分子(如ATP)转移磷酸基团到特定靶分子(底物)的酶;这一过程谓之磷酸化。许多肿瘤的发生是由某些与生长相关的“激酶”发生突变导致异常活化引起的,因而针对这些突变激酶的抑制剂能够有效抑制这些激酶的活性,从而达到抑制癌细胞增长的目的。

【细胞】免疫治疗

肿瘤免疫治疗是应用免疫学原理和方法,提高肿瘤细胞的免疫原性和对效应细胞杀伤的敏感性,激发和增强机体抗肿瘤免疫应答,并应用免疫细胞和效应分子输注宿主体内,协同机体免疫系统杀伤肿瘤、抑制肿瘤生长,是一种相对安全,有效的肿瘤治疗方法。为了满足这些需求,科佰生物为您提供肿瘤免疫稳定细胞株,包含多种热门免疫靶点,助力免疫治疗药物的研发,另外,这类稳定株还可以被用来筛选针对免疫靶点蛋白的高亲和性的抗体。

【细胞】耐药细胞

肿瘤细胞对化疗药物产生耐药性是肿瘤治疗失败的重要因素之一,成为目前阻碍肿瘤治疗的绊脚石。因此,探索肿瘤细胞产生耐药的原因以及如何改善肿瘤细胞对化疗药物耐药仍是目前研究的热点和难点。肿瘤细胞耐药的产生是一个复杂的过程,它的机制广泛牵涉到药物代谢学、病理学、生理学等多个学科,这就决定了肿瘤细胞对化疗药物产生耐药的机制是复杂的,因此体外建立化疗药物耐药细胞株仍然是研究肿瘤细胞耐药机制的重要方法。

【细胞】信号调控

 科佰生物的报告基因质粒,基于内部自主优化的载体系统。  

【标准品】Mutation

Mutation包含SNP、indel,涉及的基因包含EGFR\KRAS\NRAS\HRAS\BRAF\PIK3CA等等,在临床上有重要的意义AKT1ALKAPCARID1AATMB2MBRAFBRCA1BRCA2CCND1CDK4CDKN2ACREBBPCTNNB1DNMT3AEGFREP300ERBB2ERBB3EZH2FBXW7FGFR2HRASIDH1IDH2JAK2KRASMAP2K1NFE2L2NRASPIK3CAPIK3R1PPP2R1APTENPTPN11RAC1RHEBRHOARQCD1RXRASF3B1SMAD4SOS1TP53U2AF1XPO1    热门基因列表,点击直达

【标准品】Fusion

基因融合分为DNA translocation和RNA fusion,对应提供DNA和RNA。 ABL1ALKETV6FGFR1FGFR2FGFR3KMT2ANTRK1NTRK2NTRK3RETROS1热门基因列表,点击直达

【标准品】CNV

CNV参考品主要是指拷贝数的变异,分为loss和gain(amplication).

【标准品】其他类别

科佰生物陆续推出其他类型的标准品产品线,敬请期待!

  • 名称: SLC34A2-ROS1 [G2032R]/BaF3

询价

CBP73192
I. Introduction

Cell Line Name:

SLC34A2-ROS1 [G2032R]/BaF3

Host Cell:

Ba/F3

Stability: 16 passages

Application:

Anti-proliferation assay and PD assay

Freeze Medium:

90% FBS+10% DMSO

Complete Culture Medium:

RPMI-1640+10% FBS+1 ug/ml puromycin

Mycoplasma Status:

Negative

 
II.Background

Approximately 2% of lung tumors harbor ROS1 fusions (Bergethon et al. 2012). Like ALK fusions, ROS1 fusions are more commonly found in light smokers (<10 pack years) and/or never-smokers. ROS1 fusions are also associated with younger age and adenocarcinomas (Bergethon et al. 2012).
In preclinical models, ROS1 fusions are associated with sensitivity to tyrosine kinase inhibitors that have 'off-target' activity against ROS1, such as crizotinib (Bergethon et al. 2012; Davies et al. 2012). In addition, two patients—a previously treated metastatic NSCLC patient and a 65-year-old never smoker NSCLC patient—with tumors harboring ROS1 fusions have had partial responses to crizotinib (Bergethon et al. 2012; Davies et al. 2012). In an expansion cohort of a phase I study, 50 patients with ROS1-positive NSCLC demonstrated a 72% response rate and 19.2-month median progression-free survival interval when treated with crizotinib (Ou et al. 2013; Shaw et al. 2014). In a European case study, 32 ROS1-positive NSCLC cases treated with crizotinib were retrospectively reviewed, and an 80% response rate and a 9.1-month median progression-free survival interval was calculated in this cohort (Mazières et al. 2015).​
Several different ROS1 rearrangements have been described in NSCLC. These include SLC34A2-ROS1, CD74-ROS1, EZR-ROS1, TPM3-ROS1, and SDC4-ROS1 (Figure 1; Davies et al. 2012; Rikova et al. 2007; Takeuchi et al. 2012). Clinically, the presence of a ROS1 rearrangement is detected by fluorescence in situ hybridization (FISH) with a ROS1 breakapart probe. FISH testing is not able to discern which particular ROS1 fusion is found in a clinical sample.
ROS1 rearrangements are non-overlapping with other oncogenic mutations found in NSCLC (e.g., EGFR mutations, KRAS mutations, ALK fusions, etc.; Bergethon et al. 2012).

 
III. Representative Data

1. WB of SLC34A2-ROS1 [G2032R]/BaF3expression

 

Figure 1. Protein Expression of ROS1 detected by antibody

 

2.Sanger Sequencing of SLC34A2-ROS1 Fusion and G2032R mutation

Figure 2. SLC34A2-ROS1 Fusion

 

Figure 3. ROS1 p.G2032R

 

3. Anti-proliferation assay

Figure 4. Anti-proliferation assay of two reference compounds on the SLC34A2-ROS1 [G2032R]/BaF3 Stable Cell Line.